Important Notice for Intellia Therapeutics, Inc. (NTLA) Shareholders: Potential Class Action Lawsuit
New York, NY – The Gross Law Firm, a leading securities fraud law firm, is investigating potential securities fraud on behalf of shareholders of Intellia Therapeutics, Inc. (NASDAQ: NTLA).
According to the firm’s investigation, during the period from March 1, 2023 to October 25, 2023, Intellia Therapeutics may have provided false and misleading statements and/or failed to disclose material information to the investing public.
Class Period and Eligibility
The investigation concerns whether Intellia Therapeutics and certain of its officers or directors violated securities laws. Shareholders who purchased or otherwise acquired shares of Intellia Therapeutics during the class period listed above are encouraged to contact the firm before the lead plaintiff deadline in order to discuss their potential role in the litigation.
Alleged False and Misleading Statements
The Gross Law Firm’s investigation focuses on whether the company and its management made false and/or misleading statements and/or failed to disclose information. Specifically, the investigation concerns whether the Company and its management:
- Overstated the potential market size and growth prospects of CRISPR-Cas9 gene editing technology;
- Failed to disclose known risks and challenges associated with the development of CRISPR-Cas9 gene editing technology;
- Failed to disclose the extent of competition in the CRISPR-Cas9 gene editing market;
- Failed to disclose the extent of regulatory scrutiny of CRISPR-Cas9 gene editing technology.
Impact on Individual Shareholders
If you purchased or otherwise acquired shares of Intellia Therapeutics during the class period and suffered a loss as a result of the alleged fraud, you may be able to recover your losses. The lead plaintiff deadline is approaching, so it is important that you contact the Gross Law Firm as soon as possible.
Impact on the World
The potential impact of this investigation on the biotech industry as a whole is significant. Intellia Therapeutics is a pioneer in the field of CRISPR-Cas9 gene editing technology, and its alleged misrepresentations could have far-reaching consequences. The biotech industry relies on the accuracy and transparency of publicly traded companies to make informed investment decisions. The failure of a company to provide accurate and timely information can result in significant losses for shareholders and undermine public trust in the industry.
Conclusion
The Gross Law Firm is committed to pursuing justice for shareholders who have been victimized by securities fraud. If you purchased or otherwise acquired shares of Intellia Therapeutics during the class period listed above and believe that you may have lost money as a result of the alleged fraud, we encourage you to contact us as soon as possible. The lead plaintiff deadline is approaching, so it is important that you act quickly to protect your rights.
We welcome you to contact us by email at [email protected], by telephone at 212-504-5442, or by filling out the contact form on our website, www.grosslawfirm.com/contact. You can also reach us by mail at The Gross Law Firm, 125 Broad Street, 35th Floor, New York, NY 10004.
The Gross Law Firm represents investors worldwide and accepts cases on a contingency fee basis. We are committed to providing you with excellent legal representation and recovering the maximum possible damages for your losses.
Thank you for your interest. Please note that our press release is not a commitment to take or refrain from taking any specific legal action, and it does not create an attorney-client relationship with the Gross Law Firm. We encourage you to contact us to discuss your potential case.
